Mobile

A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With HER2-Positive Locally Advanced or Metastatic Breast C...

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-004189-27

A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With HER2-Positive Locally Advanced or Metastatic Breast Cancer who Have Received Prior Trastuzumab and Taxane Based Therapy. Estudio para evaluar la eficacia y seguridad de trastuzumab emtansine en combinación con Atezolizumab o Atezolizumab con placebo en los participantes con HER2-positivo de cáncer de mama localmente avanzado o metastásico que han recibido antes Trastuzumab y terapia basada en taxano

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the efficacy of the combination of trastuzumab emtansine plus atezolizumab compared with trastuzumab emtansine plus placebo as measured by progression free survival (PFS) using Response Evaluation Criteria in Solid tumors (RECIST) v1.1. Evaluar la eficacia de la combinación de trastuzumab emtansina más atezolizumab, comparado con trastuzumab emtansina más placebo, basándose en la Supervivencia libre de progresión (SLP) usando RECIST v1.1.

Critère d'inclusion

  • Unresectable locally advanced or metastatic breast cancer (MBC),Cáncer no resecable localmente avanzado o metastásico de mama (CMM)